.png)
Exploring the Advantages
Overcoming Limitations of Live Biotherapeutics
In the promising new field of microbiome-based therapeutics, probiotics and live biotherapeutic products have fallen short, often lacking strong clinical evidence, which is likely attributed to weak engraftment and poor viability. Our Genetically Engineered Microbial Medicines (GEMM™) are designed specifically for a diseased and inflamed gut, ensuring high durability.
Beyond Probiotics
The GEMM™ Advantages
Our BioPersist™ and BioColonize™ technologies provide
bacteria with unique properties that increase bioavailability and clinical efficacy. Our genetic platforms enable bacteria to persist and colonize in an inflamed gut, distinguishing them from conventional probiotics that often perish during inflammation.
Our goal is to integrate our patented technology into various beneficial bacterial species to create GEMM™ that are effective in treating diseases in humans and animals.
.png)
At Melius MicroBiomics, our mission is to revolutionize microbiome-based therapy through the power of GEMM™. We strive to enhance medicine by offering personalized, cutting edge therapies that align with the patient’s unique microbiome. Our goal is to lead the way in microbiome-based medicine, offering better health outcomes and improving the quality of life for both humans and animals affected by these conditions.
Our Mission
_edited.png)